Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

saroglitazar

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2019
Review
2019
BackgroundSaroglitazar, a novel dual peroxisome proliferator activated receptor (PPAR) agonist, in clinical trials, has shown an… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Highly Cited
2018
Highly Cited
2018
Non‐alcoholic fatty liver disease (NAFLD) and non‐alcoholic steatohepatitis (NASH) are common clinico‐pathological conditions… Expand
Review
2016
Review
2016
Given the high prevalence and rising incidence of non-alcoholic fatty liver disease (NAFLD), the absence of approved therapies is… Expand
Review
2015
Review
2015
  • S. Joshi
  • Expert opinion on pharmacotherapy
  • 2015
  • Corpus ID: 207480895
Introduction: Diabetes and dyslipidemia are commonly associated modifiable risk factors for cardiovascular diseases. Majority of… Expand
2015
2015
Saroglitazar is a novel nonthiazolidinediones (TZD) and nonfibric acid derivative designed to act as dual regulator of lipids and… Expand
2015
2015
Cardiovascular risk reduction is an important issue in the management of patients with Type 2 diabetes mellitus. Peroxisome… Expand
  • table 2
  • table 4
  • table 6
Highly Cited
2014
Highly Cited
2014
  • R. Agrawal
  • Current drug targets
  • 2014
  • Corpus ID: 20165940
The new chemical entity (NCE) has been knocked as novel antidiabetic agent, e.g. Saroglitazar. Saroglitazar is a drug for the… Expand
Highly Cited
2014
Highly Cited
2014
BACKGROUND Dyslipidemia due to diabetes is characterized by hypertriglyceridemia and reduced levels of high-density lipoprotein… Expand
  • table 1
  • figure 1
  • table 2
  • table 3
  • figure 2
Highly Cited
2014
Highly Cited
2014
Background: Dual PPARα/γ can improve both metabolic effects and minimized the side effects caused by either PPARα or PPAR… Expand
  • table 1
  • figure 1
  • table 2
  • table 3
  • table 4
2013
2013
Background and ObjectivesDyslipidaemia is a major cardiovascular risk factor associated with type 2 diabetes mellitus… Expand
  • figure 2
  • table 1
  • figure 3
  • figure 4
  • figure 5